Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Core Insights - Labcorp Plasma Detect technology is a blood-based assay that detects molecular residual disease (MRD) from circulating tumor DNA (ctDNA) and has been highlighted in two peer-reviewed publications, indicating its significance in cancer research and treatment strategies [1][4]. Group 1: Study Findings - A study in Nature Medicine showed promising results for patients with diffuse pleural mesothelioma (DPM), where immune-based treatment regimens before surgery were safe and allowed most patients to proceed with surgery. The study also indicated that Labcorp Plasma Detect could track early disease progression and predict long-term progression-free survival [2]. - Research published in Clinical Cancer Research found that lymph fluid collected from surgical drains after head and neck cancer surgery contained more tumor DNA than peripheral blood samples, suggesting that lymph-based testing could effectively identify residual cancer and improve follow-up treatment decisions [3]. Group 2: Clinical Utility - The studies emphasize the clinical utility of Labcorp Plasma Detect in advancing cancer research by tracking early disease progression, predicting long-term outcomes, and identifying residual cancer, which can inform future treatment strategies and enhance understanding of tumor biology [4]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, employing nearly 70,000 individuals and serving clients in approximately 100 countries. The company supports over 75% of new drugs approved by the FDA in 2024 and conducts more than 700 million tests annually [5].